A Phase 3, Open Label, Randomized, Parallel, 26 Week Treatment Study Comparing LY2605541 With Insulin Glargine as Basal Insulin Treatment in Combination With Oral Anti Hyperglycemia Medications in Asian Insulin Naive Patients With Type 2 Diabetes Mellitus
Phase of Trial: Phase III
Latest Information Update: 18 Sep 2019
Price : $35 *
At a glance
- Drugs Insulin peglispro (Primary) ; Antihyperglycaemics; Insulin glargine
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Eli Lilly and Company; Eli Lilly Japan
- 31 Aug 2018 Biomarkers information updated
- 12 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 21 Jul 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.